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Abstract Histidine-rich glycoprotein (HRG) is structurally 
related to the a 2 - H S glycoprotein/fetuin family of mammalian 
plasma proteins; both belong to the cystatin superfamily of 
proteins. We expressed recombinant human HRG and 0C2-HS in 
Sf9 insect cells for functional analysis. Recombinant HRG bound 
heparin and fibrinogen while rx2-HS did not. Both proteins 
inhibited the formation of apatite, recombinant HRG (IC5 0 
~ 1 (iM) with 2-fold lower molar activity than a 2 - H S (IC5 0 
~ 0.5 uM). The inhibition in vitro of apatite formation suggests 
a new function for plasma HRG protein, inhibition of phase 
separation in blood vessels. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Histidine-rich glycoprotein (HRG) , also called histidine-
proline-rich glycoprotein, is a mammalian plasma protein be-
longing to the cystatin superfamily [1]. It is known to interact 
with several ligands including metal ions [2], heme [3], heparin 
[4], plasminogen [5], fibrinogen [6] and thrombospondin [7]. 
The physiological role of histidine-rich glycoprotein is still 
unclear [8], al though an involvement in T-cell regulation [9] 
and fibrinolysis [5] have been suggested. Primary structures 
were determined for the human [10] and the rabbit [11] 
H R G while partial amino acid sequences are known for the 
bovine protein [12]. The sequence data suggest a common 
multidomain structure for both proteins. The aminoterminal 
part of the molecule contains two tandemly arranged cystatin-
like domains, while the carboxyterminal part contains a re-
gion unusually rich in histidine arranged between two proline-
rich regions [11]. Amino- and carboxyterminal parts of the 
molecule are linked by a disulfide bond [12]. 
The overall structural features of H R G are similar to CH2-HS 
glycoprotein/fetuin, another member of the cystatin superfam-
ily. Collectively called fetuins, these proteins consist of two 
aminoterminally located cystatin-like domains followed by a 
proline-rich carboxyterminal domain connected to the amino-
terminal domain by a disulfide bond [13]. The most striking 
difference between H R G and fetuin is that H R G contains the 
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histidine-rich region with 12 tandem repeats of the sequence 
Gly -His -Hi s -P ro -His . This region is proposed to mediate 
binding of H R G to heparin and metal ions and it might target 
the protein to (sub)endothelial surfaces. Unlike H R G fetuin 
has never been shown to interact with heparin, components of 
the fibrinolytic system or extracellular matrix. Fetuin does, 
however, accumulate in bones and teeth by interacting with 
the anorganic phase [14]. Based on this observation we have 
recently shown that fetuins inhibit apatite formation in vitro 
and in mineralising calvaria cells suggesting a possible role of 
these proteins in calcium homeostasis and mineralisation [15]. 
We generated by homologous recombination mice lacking the 
fetuin gene, Ahsg [Jahnen-Dechent et al., in preparation]. The 
mice were phenotypically normal showing no defect causally 
related to phase separation or spontaneous calcification in 
blood. We reasoned that proteins structurally similar to fe-
tuins might exert similar biological roles to act as backup 
systems. Intrigued by the similar structures of H R G and fe-
tuin we examined the influence of H R G on apatite formation. 
We show that recombinant human H R G expressed in Sf9 
insect cells is indeed able to inhibit apatite formation in vitro 
in a similar fashion as human a 2 - H S glycoprotein/fetuin. 
Therefore, H R G might contribute to the inhibition of phase 
separation and unwanted calcification in blood vessels, by 
virtue of its affinity to heparin-like molecules and fibrinogen 
possibly localized at sites of vascular repair. 
2. Materials and methods 
2.1. Protein expression in Sf9 insect cells 
The cDNA encoding human histidine-rich glycoprotein has been 
described [10]. It was subcloned into the baculovirus transfer vector 
pVL1393 as an EcoRl fragment. Sf9 cells were contransfected with 
this plasmid and BaculogoldaSl-DNA (Pharmingen). Recombinant vi-
rus expressing HRG was cloned by limited dilution. Baculovirus-
mediated expression of human a2-HS-glycoprotein/fetuin in insect 
cells has been described [15]. Proteins were expressed in serum-free 
medium SF900II (Life Technologies, Inc.). HRG as well as fetuin 
were purified by immunoaflinity chromatography from the medium 
6 days after infection. Bound proteins were eluted with 0.2 M glycine, 
pH 2.3, and subsequently desalted utilizing Centricon spin dialysis 
units (Amicon). 
2.2. Electrophoresis and blotting procedures 
SDS-PAGE and chemiluminescence immunoblots were done as de-
scribed [16]. Polyclonal antiserum raised against human HRG has 
been described [10]. Lectin blots with Sambucus nigra agglutinin and 
Galanthus nivalis agglutinin were performed using the DIG-glycan 
differentiation kit (Boehringer Mannheim) according to the manufac-
turer's protocol. 
2.3. Binding experiments 
Heparin-Sepharose and fibrinogen were obtained from Sigma. 
Binding to heparin was analyzed by passing supernatant of infected 
Sf9 cells over a heparin-Sepharose containing column. The superna-
tants were diluted 5-fold in 50 mM HEPES, pH 6.8 or pH 7.4. Bound 
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proteins were eluted by 2 M NaCl in buffer. The fractions were an-
alyzed by SDS-PAGE and subsequent immunoblotting. Binding to 
fibrinogen was analyzed by a modified ELISA technique. Fibrinogen 
was coated overnight onto the surface of microtiter plates at a con-
centration of 10 ug/ml. Free binding sites were blocked with incuba-
tion buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Triton 
X-100, 0.25% gelatin). The plates were then incubated with superna-
tant of infected cells in a 2" dilution series starting with a 20-fold 
dilution. Incubations were performed in the presence of 0.5 mM 
ZnCt or 1 mM EDTA. Fibrinogen-bound proteins were detected 
by incubation with antisera against HRG and fetuin, respectively, at 
a 5000-fold dilution in buffer. Bound antibodies were visualized by 
peroxidase-conjugated anti-rabbit IgG antibodies utilizing the sub-
strate 2,2'-azino-di[3-ethylbenzthiazoline sulfonate]. 
2.4. Inhibition of apatite formation 
A buffered salt solution (50 mM Tris-HCl, pH 7.4, 4.8 mM CaCl2, 
2X 106 cpm 45CaCl2, 1.6 mM Na2HP04) with increasing amounts of 
purified HRG, fetuin or bovine serum albumin was incubated at 37°C 
for 90 min. Precipitates were collected by centrifugation, dissolved in 
0.5% acetic acid and analyzed by liquid scintillation counting. All 
incubations were done in triplicate and repeated at least two times. 
2.5. Extraction of proteins from bone 
Human epiphysial bone remnants trimmed during routine surgery 
(Klinik filr Unfallchirurgie, Universitatsklinik Mainz) were ground to 
a powder in liquid nitrogen. Bone proteins were extracted according 
to the procedure of Termine et al. [17]. The second extract done with 
guanidine and EDTA was dialyzed against water and analyzed by 
SDS-PAGE and subsequent immunoblotting. 
3. Results 
Human histidine-rich glycoprotein and human a2-HS-gly-
coprotein were expressed in Sf9 insect cells by infection with 
recombinant baculovirus. Fig. 1 (left panel) shows a stained 
polyacrylamide gel analysis of HRG isolated from plasma 
(lane 1) and from the supernatant of virus infected Sf9 cells 
(lane 2). The apparent molecular mass of recombinant HRG 
was smaller in comparison to the HRG purified from plasma. 
Under reducing conditions, recombinant HRG migrated at 
66 kDa whereas the molecular mass of the reduced plasma 
form was 78 kDa as published [18]. We have previously de-
termined that a similarly reduced apparent molecular mass of 
recombinant 0C2-HS (45 kDa) compared to plasma a2-HS 
(60 kDa) was due to incomplete N-glycosylation in the Sf9 
expression system [15]. Therefore we analyzed the carbohy-
drate moieties of purified HRG by lectin blotting using Sam-
bucus nigra agglutinin (SNA) and Galanthus nivalis agglutinin 
(GNA). Fig. 1 shows that plasma HRG, like the positive 
control proteins, 012-HS and bovine fetuin (not shown), were 
all detected by SNA indicating complex N-glycosylation with 
terminal sialic acid residues. In contrast, the recombinant 
form of HRG was not detected by SNA, but reacted positive 
with GNA, which is specific for terminal mannose residues. 
Thus, the recombinant proteins expressed in Sf9 insect cells 
are partially glycosylated lacking terminal sialic acid, which 
results in the reduced apparent molecular masses observed 
upon reducing SDS-PAGE. 
Next we assayed the binding of recombinant HRG and 
012-HS to heparin using affinity chromatography and immu-
noblotting. As shown in Fig. 2A, recombinant HRG bound 
strongly to heparin-Sepharose at pH 6.8 (Fig. 2A, lane 3) 
and, to a lesser extent at pH 7.4 (Fig. 2A, lane 6) as described 
earlier for plasma HRG [19]. In the same assay CC2-HS failed 
to bind heparin-Sepharose at pH 6.8 or at pH 7.4, but was 
quantitatively recovered in the unbound column effluent in 
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Fig. 1. Carbohydrate analysis of plasma and recombinant HRG. 
1 ug of purified plasma HRG (lane 1) and recombinant HRG 
(lane 2) were subjected to SDS-PAGE and stained with Coomassie 
Blue (left panel). Two identical replicas were blotted onto nitrocellu-
lose and incubated with the DIG-conjugated lectins Sambucus nigra 
agglutinin, SNA (center panel) and Galanthus nivalis agglutinin, 
GNA (right panel) utilizing the DIG glycan differentiation kit 
(Boehringer Mannheim). 
each case (Fig. 2A, lanes 2 and 5). Binding of proteins to 
fibrinogen was analyzed by a modified ELISA technique. 
Fig. 2B illustrates that recombinant HRG bound fibrinogen 
in a concentration-dependent and saturable manner (Fig. 2B, 
□,■). Furthermore, the binding was enhanced in the presence 
of divalent Zn2+ ions (Fig. 2B, ■ vs. □). In contrast, (X2-HS 
did not bind fibrinogen in the absence of Zn2+ and only 
weakly in the presence of Zn2+ ions (Fig. 2B • vs. O). In 
summary, our results indicate that recombinant HRG has 
the same functional properties as the native protein with re-
spect to heparin and fibrinogen binding. 
Extending previous investigations [15] we asked, if purified 
recombinant HRG could inhibit the formation of apatite. Fig. 
3 illustrates a typical precipitation assay where HRG dose-
dependently inhibited the formation of apatite with an IC50 
of ~ 1 |J,M. As a positive control, 0C2-HS likewise inhibited 
with an IC50 value of <~0.5 (xM. In this assay BSA, a negative 
control protein at concentrations up to 10 (tM did not inhibit 
apatite precipitation. Pretreatment of the test proteins with 
proteinase K completely abolished the inhibitory activity in-
dicating that indeed the protein moieties accounted for the 
inhibition of apatite formation (data not shown). 
We asked, if the ability to bind nascent apatite demon-
strated in Fig. 3 would be sufficient to target HRG to bone 
tissue. ot2-HS glycoprotein/fetuin is known to accumulate in 
bone mineralized matrix while no predominant localisation of 
HRG outside the plasma pool has been reported to date. To 
this end we analyzed human cortical bone extracts by immu-
noblotting. Fig. 4 shows that the antiserum raised against 
human plasma HRG readily detected HRG in serum, but 
not in bone extract while a2-HS was readily detected in 
both samples. Therefore, HRG does not seem to concentrate 
in bones, although it can interact with apatite. 
4. Discussion 
Like most body fluids blood contains calcium and phos-
phate ions at relatively high concentrations raising the possi-
bility that a spontaneous formation of apatite could occur 
very easily under (patho)physiological conditions. Proteins 
have been identified to inhibit the formation of calcium salts 
in body fluids, saliva [20], pancreatic juice [21] and urine [22]. 
Plasma proteins have also been described to inhibit apatite 
formation in vitro [23] and albumin has been shown to con-
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Fig. 2. Binding of recombinant HRG and a2-HS to heparin and fibrinogen. A: Supernatant of Sf9 cells infected with virus expressing HRG 
(upper panel) or a2-HS (lower panel) was diluted 5-fold in 50 mM HEPES, adjusted with NaOH to pH 6.8 (lanes 1-3) or 7.4 (lanes 4-6) and 
applied onto a column containing heparin-Sepharose. Bound proteins were eluted with 2 M NaCl in buffer. 10 u.1 of the loaded solution (lanes 
1 and 4), the flow-through (lanes 2 and 5) and the eluate (lanes 3 and 6) were subjected to SDS-PAGE and subsequently blotted onto nitrocel-
lulose. HRG and a2-HS were detected by antisera as described in Fig. L B : Fibrinogen was coated onto microtiter plates at a concentration 
of 10 |ig/ml. Supernatant of Sf9 cells infected with virus expressing HRG (□,■) or a2-HS (o,») was applied at a 2™ serial dilution in incubation 
buffer in the presence (•,■) or absence (O.D) of 0.5 mM ZnCl2. Bound proteins were detected with antisera against HRG or a2-HS (both at a 
5000-fold dilution) and subsequent incubation with peroxidase-labelled anti-rabbit IgG antibodies. Absorbance at 410 nm was measured after 
incubation with the substrate 2,2'-azino-di[3-efhylbenzthiazoline sulfonate]. 
tribute to this effect because of its high concentrations in 
blood [24]. The need for and the existence of inhibitory mech-
anisms of ectopic calcification has been unequivocally demon-
strated by recent genetic experimentation. The targeted dis-
ruption of the gene for matrix GLA (gamma-glutamic acid) 
protein in mice resulted in spontaneous, lethal calcification of 
arteries and cartilage [25]. We have recently demonstrated that 
fetuin is an effective inhibitor of apatite precipitation, as the 
inhibitory activity of total serum protein drops about 30% 
after depletion of fetuin by affinity absorption [15] or in trans-
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Fig. 3. Inhibition of apatite formation by recombinant HRG and 
a2-HS. A buffered salt solution (50 mM Tris-HCl, pH 7.4, 4.8 mM 
CaCl2, 2X10
6 cpm 45CaCl2, 1.6 mM Na2HP04) also containing at 
the indicated concentration purified HRG (•), a2-HS (■) or bovine 
serum albumin (♦) was incubated at 37°C for 90 min. Precipitates 
were collected by centrifugation, dissolved in 0.5% acetic acid and 
analyzed by liquid scintillation counting. Incubations were done in 
triplicate. Bars indicate the SEM within triplicates. Note that tripli-
cate readout was essentially identical at low and high protein inhibi-
tor concentrations. 
genie mice lacking the fetuin gene [Jahnen-Dechent et al., in 
preparation]. Obviously, the remainder of plasma proteins can 
compensate the loss of fetuin. Therefore, we started to identify 
further proteins contributing to the overall inhibitory activity 
of serum. Here we show that HRG, like (X2-HS a protein of 
the cystatin superfamily, can also inhibit apatite formation in 
vitro. The data presented in this paper raise the possibility 
that proteins of the cystatin superfamily in general serve a 
function as inhibitors of phase separation. Notably, a third 
member of this family, salivary cystatin, is an inhibitor of salt 
precipitation in saliva [26] and a fourth cystatin-like protein 
with unknown function, SPP24 [27], is expressed in liver and 
in bone. 
Both HRG and 0C2-HS/fetuin presumably contribute to a 
larger pool of plasma inhibitors yet they might exert their 
functions in separate locations due to their respective binding 
characteristics. Like plasma HRG, recombinant HRG avidly 
HRG 
a2-HS 
plasma bone 
Fig. 4. Detection of HRG and a2-HS in plasma and bone. Proteins 
were extracted from adult human bone. 0.02 ul human plasma 
(lane 1) and 1 ug of the extracted bone proteins (lane 2) were sub-
jected to SDS-PAGE and subsequently blotted onto nitrocellulose. 
HRG and a2-HS were detected by antibodies and enhanced chemo-
luminescence. 
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bound heparin and fibrinogen. H R G therefore likely accumu-
lates at sites of tissue damage with concomitant exposure of 
subendothelial surfaces. At these sites H R G could prevent 
ectopic calcification by inhibiting apatite precipitation. In con-
trast, 012-HS/fetuin does not bind to heparin and fibrinogen 
and therefore remains in circulation until it is eventually se-
questered to the mineral phase upon passage through bone 
tissue. 
In summary this paper describes a hitherto unknown in 
vitro activity of H R G , namely inhibition of spontaneous apa-
tite formation. The (patho)physiological relevance of this find-
ing needs further examination. 
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